Abstract
G protein signaling is an extremely complex event that is involved in almost every cellular process. As such, G protein-coupled receptors are the most commonly found type of transmembrane receptors used by cells to initiate intracellular signaling events. However, the widely accepted model of cyclical GDP-GTP exchange in response to ligand binding to 7TMRs, followed by dissociation of the G protein subunits and activation of intracellular signaling cascades, has repeatedly been challenged in recent years. Some of the exceptions that have been brought forth include signaling by a non-dissociated, rearranged heterotrimer and the existence of “reverse-mode”, active G proteins that interact with active receptors. Here, we focus on Gαi/o, one of the common Gα classes, and outline a major exception to the classical model, that of G protein coupling to RTKs. We then describe a novel concept in Gαi/o signaling, namely that the pathways induced by agonist binding circumvent the typical signaling pathways responsive to decreases in the second messenger cAMP, via adenylyl cyclase inhibition.
Keywords: Adenylyl-cyclase independent, Gαi, G protein-coupled receptors, receptor tyrosine kinase.
Current Vascular Pharmacology
Title:Atypical Gαi Signal Transduction
Volume: 12 Issue: 2
Author(s): Raissa Perrault and Peter Zahradka
Affiliation:
Keywords: Adenylyl-cyclase independent, Gαi, G protein-coupled receptors, receptor tyrosine kinase.
Abstract: G protein signaling is an extremely complex event that is involved in almost every cellular process. As such, G protein-coupled receptors are the most commonly found type of transmembrane receptors used by cells to initiate intracellular signaling events. However, the widely accepted model of cyclical GDP-GTP exchange in response to ligand binding to 7TMRs, followed by dissociation of the G protein subunits and activation of intracellular signaling cascades, has repeatedly been challenged in recent years. Some of the exceptions that have been brought forth include signaling by a non-dissociated, rearranged heterotrimer and the existence of “reverse-mode”, active G proteins that interact with active receptors. Here, we focus on Gαi/o, one of the common Gα classes, and outline a major exception to the classical model, that of G protein coupling to RTKs. We then describe a novel concept in Gαi/o signaling, namely that the pathways induced by agonist binding circumvent the typical signaling pathways responsive to decreases in the second messenger cAMP, via adenylyl cyclase inhibition.
Export Options
About this article
Cite this article as:
Perrault Raissa and Zahradka Peter, Atypical Gαi Signal Transduction, Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/1570161112666140226122512
DOI https://dx.doi.org/10.2174/1570161112666140226122512 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Development of Cannabinoid CBII Receptor Agonists for the Treatment of Central Neuropathies
Central Nervous System Agents in Medicinal Chemistry Radiotherapy Improvements by Using Au Nanoparticles
Recent Patents on Nanotechnology Psychosocial Risk Factors Related to Ischemic Heart Disease in Women
Current Pharmaceutical Design Conference Report: 14th International Congress on Amino Acids, Peptides and Proteins, Vienna, Austria, August 3-7, 2015
CNS & Neurological Disorders - Drug Targets The Role of QSAR and Virtual Screening Studies in Type 2 Diabetes Drug Discovery
Medicinal Chemistry Genetics in the Clinical Decision of Antiplatelet Treatment
Current Pharmaceutical Design Safety of Drug Eluting Stents: Current Concerns and Controversies
Current Drug Safety Expressions of eNOS3 and Ve-Cadherin in Microvascular Endothelium at 7-Day of Reperfused Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Alzheimer’s Disease: A Contextual Link with Nitric Oxide Synthase
Current Molecular Medicine Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors
Current Medicinal Chemistry Cell-Penetrating Peptides as a Potential Drug Delivery System for Effective Treatment of Diabetes
Current Pharmaceutical Design MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Pharmacological Therapy of Pericardial Diseases
Current Pharmaceutical Design Hypothalamic AMP-activated Protein Kinase as a Regulator of Food Intake and Energy Balance
CNS & Neurological Disorders - Drug Targets Non-Antidepressant Pharmacologic Long-Term Treatment of Panic Disorder
Current Clinical Pharmacology The C242T CYBA Polymorphism as a Major Determinant of NADPH Oxidase Activity in Patients with Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Bicyclic 6 + 6 Systems: Advances in the Chemistry of Heterocyclic Compounds Incorporated Pyrimido[1,2-a]Pyrimidine Skeleton
Mini-Reviews in Organic Chemistry